Skip to main content
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. — Investor Relations & Filings

Ticker · AQST ISIN · US03843E1047 US Manufacturing
Open in API
Filings indexed 607 across all filing types
Latest filing 2019-09-17 Capital/Financing Update
Country US United States of America
Listing US AQST

About Aquestive Therapeutics, Inc.

https://aquestive.com/

Aquestive Therapeutics is a pharmaceutical company that develops and commercializes medicines using its proprietary PharmFilm® technology. This oral film drug delivery system provides a non-invasive and convenient alternative to conventional therapies, such as injections, by enabling the oral administration of complex molecules. The company's development pipeline is focused on addressing unmet medical needs in central nervous system (CNS) disorders and severe allergic reactions. Key product candidates include Anaphylm™, an epinephrine sublingual film for the emergency treatment of anaphylaxis, and Libervant®, a diazepam buccal film for the management of seizure clusters.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 95% confidence The document is a Form 424B5 prospectus filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an equity distribution agreement for the sale of common stock, including terms of the offering, risk factors, use of proceeds, dilution, and plan of distribution. The document is a registration and offering prospectus related to capital raising activities, specifically an 'at the market offering' of common stock. It is not a financial report, earnings release, or management discussion, but rather a capital/financing update describing the terms and conditions of a stock offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, supporting a high confidence in this classification.
2019-09-17 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a Form 424B5 prospectus filed pursuant to Rule 424(b)(5) related to the resale of common stock by selling stockholders. It describes the terms of a secondary offering of shares, details about the selling stockholders, use of proceeds, risk factors, and other offering-related information. It is a registration statement prospectus supplement for a securities offering, not a financial report, earnings release, or management discussion. The document is a capital markets filing related to financing activities, specifically a secondary offering of shares by selling stockholders. Therefore, it fits best under the category Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, not just an announcement or brief notice, so it is not an RPA or RNS. Confidence is high given the clear identification as a prospectus for a securities offering.
2019-09-17 English
Regulatory Filings 2019
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Due to the lack of discernible information and the inability to identify the nature of the document, it cannot be classified into any specific filing category based on the given definitions. According to the fallback rule, documents that do not neatly fit into any category should be classified as Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable.
2019-09-16 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is a formal communication related to a securities registration process, not a financial report or detailed filing. The document length is short (1413 characters), and it does not contain financial data or detailed report content. It is essentially a regulatory communication or filing related to registration effectiveness. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and communications that do not fit other specific categories.
2019-09-16 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes details about the types of securities to be offered (common stock, preferred stock, debt securities, warrants, units, rights), the maximum aggregate offering price, and other registration fee calculations. The document is a registration statement prospectus, not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or notice, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2019-09-11 English
SCHEDULE 13G HOLDINGS REPORT
Major Shareholding Notification
2019-09-09 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.